Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | DRD4 | P21917 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6255661 | 0.92 | HRH3 (0.49) | L3MBTL1PPARAHRH3 | |
| SCHEMBL9935752 | 0.84 | LTA4H (0.53) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL12868339 | 0.83 | DRD2 (0.52) | L3MBTL1PPARADRD2DRD4DRD3 | |
| SCHEMBL9592060 | 0.82 | SMN1; SMN2 (0.53) | NPC1HRH3MEN1KMT2A | |
| SCHEMBL16637914 | 0.82 | ALDH1A1 (0.54) | L3MBTL1PPARADRD2DRD4DRD3 | |
| SCHEMBL9935748 | 0.82 | HRH3 (0.43) | L3MBTL1PPARAHRH3 | |
| SCHEMBL18034737 | 0.82 | TDP1 (0.52) | L3MBTL1NPC1HRH3KMT2A | |
| SCHEMBL8095513 | 0.82 | KCNA3 (0.54) | L3MBTL1PPARA | |
| SCHEMBL21577415 | 0.80 | TP53 (0.45) | NPC1MEN1KMT2A | |
| SCHEMBL16745624 | 0.79 | ENPP2 (0.47) | PPARAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-20160235706-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20140163025-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| WO-2014086712-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163025-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPBAR1, GPR52 | L3MBTL1 4431/4885PPARA 156/4885DRD2 799/4885 |
| US-20160235706-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPBAR1, GPR52 | L3MBTL1 4431/4885PPARA 156/4885DRD2 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.